Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 51

OLIG2 Targeting in DIPG using the novel small molecular inhibitor ...

Diffuse Intrinsic Pontine Glioma (DIPG) is an incurable brain stem glioma predominantly arising in young children, better options to treat this aggressive disease are urgently needed. Oligodendrocyte transcription factor 2 (OLIG2) is mostly expressed in restricted domains of the brain and spinal cord ventricular zone which give rise to oligodendrocytes and ...

Modulation of intra-tumor hypoxia to sensitize DIPG irradiation and initiate ...

Malignant gliomas in specific region like brain pons are not curable as they cannot be surgically resected and are only transiently benefiting from local irradiation and in some cases from targeted therapies. These aggressive brain tumors are molecularly well known as they are characterized by a driver mutation. This abnormality ...

TARGETING NEURONAL ACTIVITY-REGULATED DIPG INFILTRATION (2017)

DIPG is characteristically infiltrative (i.e. diffuse and intrinsic), and this infiltrative/invasive behavior is destructive both in the brainstem and in other areas of the central nervous system to which DIPG spreads during the course of the disease. In work previously funded by the Cure Starts Now and the ...

Targeting DIPG through pharmacological activation of mitochondrial biogenesis: as in ...

Diffuse intrinsic pontine gliomas (DIPG) are infiltrative, highly aggressive pediatric brainstem tumors with limited therapeutic options. Despite international efforts to improve outcome, DIPG show poor response to conventional radiation and chemotherapeutic strategies. Only within the last decade have studies really begun to decipher the molecular mechanisms behind DIPG tumorigenesis, with ...

Targeting EZH2 as a theraputic strategy in DIPG

Malignant brain tumors are the leading cause of cancer-related mortality in children (1), and diffuse intrinsic pontine glioma (DIPG) is one of the most devastating, with a median survival of <1 year following treatment with radiation therapy (2). Despite more than 250 clinical trials over the past 30 years (3), not a single chemotherapeutic agent ...